Inokain - instructions for use, dose, side effects, contraindications

Active substanceOxibuprocaineOxibuprocaine

Similar drugsTo uncover

Benoxi

drops d / eye

Unimed Pharma s.r.o. The Slovak Republic

Inokain®

drops d / eye

Sentiss Pharma Pvt. Ltd. India

Dosage form: & nbspeye drops

Composition:

1 ml of the preparation contains:

active substance: benoxinate hydrochloride (hydroxybuproquine hydrochloride) 4 mg;

Excipients: benzalkonium chloride 0.1 mg, boric acid 19.0 mg, disodium edetate 0.1 mg, sodium chloride 8.0 mg, water for injection up to 1 ml.

Description:A clear, colorless solution.

Pharmacotherapeutic group:Local anesthetic

ATX: & nbsp

S.01.H.A Local Anesthetics

S.01.H.A.02 Oxibuprocaine

Pharmacodynamics:

Local anesthetic; blocks nerve endings. It penetrates well into tissues at local appointments. Compared with tetracaine and other local anesthetics, it has less irritating effect on conjunctiva and cornea.

Surface anesthesia of the conjunctiva and cornea occurs in 30 seconds and lasts 15 minutes.

Pharmacokinetics:

Inokain® easily penetrates the stroma of the cornea after a single instillation of it into the conjunctival cavity. During the next 15 minutes, the stromal concentration of the drug decreases quantitatively, which causes a 12-15 minute period of anesthesia with a single instillation.

Indications:Local anesthesia in ophthalmology:

- measurement of intraocular pressure (tonometry);

- Gonioscopy;

- diagnostic scrapings of the conjunctiva;

- extraction of foreign bodies and stitches from the cornea and conjunctiva;

- short-term surgical interventions on the cornea and conjunctiva.

Contraindications:Individual hypersensitivity to the components of the drug.

Pregnancy and lactation:Sufficient experience in the use of the drug during pregnancy, breast-feeding and in children there. It is possible to use Inokain ® for the treatment of children, pregnant and lactating mothers as prescribed by the attending physician, if the expected curative effect exceeds the risk of possible side effects.

Dosing and Administration:Locally, instilled in the conjunctival sac by 1 drop.

Long-term anesthesia (up to 1 hour) provides a 3-fold instillation with an interval of 4-5 minutes.

Side effects:

Short-term tingling sensation, burning and congestion hyperemia; allergic reactions; keratitis (rarely).

Overdose:

Data on drug overdose are absent.

Interaction:

In the literature, negative or positive effects are not described with simultaneous administration of oxybuprocain and other conventionally used eye drops into the conjunctival cavity.

It is noted that oxybuproquin can theoretically reduce the antibacterial activity of sulfonamides.

Special instructions:

Use only for instillations in the conjunctival sac. Do not use for injection.

Prolonged, repeated and prolonged use (as well as other local anesthetics), can lead to stable opacity of the cornea.

It is not intended for long-term therapy in the complex treatment of eye diseases.

During anesthesia, it is necessary to protect the eye from irritating chemical influences, foreign bodies and friction.

Form release / dosage:

Eye drops, 0,4%.

Packaging:

5 ml in a plastic bottle-dropper with a screw cap. Each vial-dropper along with the instruction for use is placed in a cardboard box.

5 ml in a bottle of dark glass, closed with a rubber stopper, crimped aluminum cap with a safety plastic cap. One glass bottle with a sterile dropper packed in a plastic bag is placed in a cardboard box along with instructions for use.

Storage conditions:

At a temperature of no higher than 25 ° C in a dark place.

Do not freeze.

Keep out of the reach of children.

Shelf life:

2 years.

After opening the vial, the drug should be used within 1 month.

Do not use after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N012272 / 01

Date of registration:04.04.2008 / 04.12.2013

Expiration Date:Unlimited

The owner of the registration certificate:Sentiss Pharma Pvt. Ltd.Sentiss Pharma Pvt. Ltd. India

Manufacturer: & nbsp

SENTISS PHARMA Pvt. Ltd India

Representation: & nbspSENTISS RUSS LLCSENTISS RUSS LLCRussia

Information update date: & nbsp31.10.2017

Illustrated instructions

Instructions

Inokain® (Inokain®)